|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dr. Paul Shields, COO of Enteris BioPharma, discusses the changing face of the CDMO industry and how his company plans to leverage its newly expanded CDMO operations to take advantage of a variety of growth opportunities to build deeper partnerships.
|
|
|
Josef Bossart, PhD, introduces, in a series of short articles, a qualitative model to help understand and visualize the potential of a product with prescribers, patients, and payors. This simple model can help weed out product ideas that may at first glance seem attractive but offer little potential in the real world.
|
|
|
Ashley Jacobi says while there are many ever-improving tools available to scientists performing ground-breaking research, and the potential of CRISPR genome editing appears limitless, there remain challenges that need to be overcome to realize the technology’s full potential.
|
|
|
Robert Davidson says there have been significant advances in clinical development of this novel drug delivery system, and the technology is rapidly moving from just a theory to practical real-world application.
|
|
|
|
|
|
|
|
|

Pfanstiehl is a global leader in the manufacture of cGMP high purity, low endotoxin, low metal injectable-grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications. In addition, Pfanstiehl is a leading contract development and manufacturing organization (CDMO) specializing in the isolation, purification, custom synthesis, and scale-up development of small molecule Active Pharmaceutical Ingredients (APIs), in gram to multi-ton commercial quantities. While most ingredient manufacturers or resellers focus on other industries, such as food, cosmetics, agriculture, and/or nutritional supplements, offering only a subset of ‘pharma- grade’ ingredients, Pfanstiehl is Pharma Grade through and through. Click here for more.
|
|
|
|
|
|
 |
|
Cyclerion Therapeutics, Inc. recently announced it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the….
|
|
 |
|
In direct response to the rapid growth of the recently launched Human Factors + (HF+) program, Noble, an Aptar Pharma company, recently announced the….
|
|
 |
|
Bayer AG recently announced that BlueRock Therapeutics (BlueRock) successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a….
|
|
 |
|
Akoya Biosciences, Inc. recently announced a collaboration with AstraZeneca to advance new multiplex immunofluorescence (mIF) workflows and spatial biomarker signatures….
|
|
|
|
|
Upcoming eNewsletter Features:
June 23 – Controlled Release
June 30 – Drug Delivery
|
|
|
|
|
|
|
|